What is the evidence for SS-31 / Elamipretide?
SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.
DIRECT ANSWER
SS-31 / Elamipretide evidence summary.
SS-31 is no longer simply an unapproved research peptide: elamipretide now has one narrow accelerated-approval pathway, with confirmatory evidence still required.
Reviewed August 7, 2026. Each statement links to its evidence record, followed by the primary and official sources used for this answer.
Elamipretide received accelerated approval for a rare-disease indication based on a small clinical program; confirmatory work continues.
Open evidence recordA broad mitochondrial literature does not expand the approved indication beyond the label.
Open evidence recordA rare-disease approval should not be generalized to longevity or performance claims.
Open evidence recordPRIMARY & OFFICIAL SOURCES
Sources for this answer.
2 source records, with duplicates removed.